glucagon receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
Reek of Putrefaction is the debut studio album by English extreme metal band Carcass. It was released by Earache Records on 28 July 1988. It is considered the first release in the goregrind genre, which the band pioneered.
Joanna Bryson and Helena Malikova have pointed to Big Tech's potential interest in promoting the AI Cold War narrative, as technology companies lobby for less onerous regulation of AI in the US and the EU. A factual assessment of the existing AI capabilities of different countries shows a less binary reality than portrayed by the AI Cold War narrative. The AI Cold War started as a narrative but it could turn into a self-fulfilling prophecy and fuel an arms race, not only because of corporate interests but also because of the existing interests at different national security departments. Regarding cyber power, the International Institute for Strategic Studies published a study in June 2021, which argued that the online capabilities of China have been exaggerated and that Chinese cyber power is at least a decade behind the US, largely due to lingering security issues.
Aspergillus luchuensis (synonym Aspergillus awamori, Aspergillus inuii, Aspergillus nakazawai and Aspergillus coreanus, クロコウジキン / 黒麹菌 'kuro kōji-kin') Aspergillus niger (synonym Aspergillus batatae, Aspergillus aureus or Aspergillus foetidus, Aspergillus miyakoensis and Aspergillus usamii including A. usamii mut. shirousamii) Aspergillus tubingensis (synonym Aspergillus saitoi and A. saitoi var. kagoshimaensis) White kōji (Aspergillus kawachii) is an albino variant of Aspergillus luchuensis. It is typically used in the production of shōchū.
A 2019 systematic review suggests, based on very limited evidence, that oral administration (swallowing) of glucose (tabs) leads to a bigger improvement in blood glucose levels when compared to buccal administration (dextrose gel). This same review reported that, based on limited evidence, no difference was found in plasma glucose when administering combined oral and buccal glucose compared to only oral administration. In the very specific setting of children with concomitant malaria or respiratory tract infection, sublingual administration of sucrose (table sugar) may be more effective than oral administration. This entails dissolving the table sugar under the tongue.
"The Omega Glory" is the twenty-third episode of the second season of the American science fiction television series Star Trek. Written by Gene Roddenberry and directed by Vincent McEveety, it was first broadcast March 1, 1968. In the episode, Captain Kirk must find the cure to a deadly disease and put an end to another Starfleet captain's cultural interference. The story was one of three outlines submitted for selection as the second pilot of Star Trek, the others being "Mudd's Women" and "Where No Man Has Gone Before". Retrospective reviews of "The Omega Glory" rank it among the worst episodes of the original series.
Sources: en.wikipedia.org
Dutasteride, sold under the brand name Avodart among others, is a medication primarily used to treat the symptoms of a benign prostatic hyperplasia (BPH), an enlarged prostate not associated with cancer. It is also used to treat pattern hair loss in men as an off-label medication and as an approved medication in South Korea, Japan, and Taiwan. A few months may be required before benefits occur. It is usually taken by mouth; however, topical versions exist for those with hair loss, which are designed to minimize systemic exposure by acting specifically on hair follicles. The most commonly reported side effects of dutasteride, although rare, include sexual dysfunction. In the largest available study of 6,729 men with BPH, 9% experienced erectile dysfunction (compared to 5.7% treated with a placebo), 3.3% experienced decreased sex drive (vs 1.6% of placebo), and 1.9% had enlarged breasts (vs 1% of placebo). Exposure during pregnancy is specifically contraindicated because antiandrogens such as dutasteride have been shown to interfere with the sexual development of male fetuses. Dutasteride was patented in 1993 by Glaxo Wellcome (later known as GSK after additional mergers) and was approved for medical use in 2001. It is available as a generic medication and as such, manufactured and exported more by India than elsewhere. In 2023, it was the 236th most commonly prescribed medication in the US with more than 1 million prescriptions.
Type 1: Separate hard lumps, like nuts (difficult to pass) Type 2: Sausage-shaped, but lumpy Type 3: Like a sausage but with cracks on its surface Type 4: Like a sausage or snake, smooth and soft (average stool) Type 5: Soft blobs with clear cut edges Type 6: Fluffy pieces with ragged edges, a mushy stool (diarrhoea) Type 7: Watery, no solid pieces, entirely liquid (diarrhoea) Types 1 and 2 indicate constipation, with 3 and 4 being the ideal stools as they are easy to defecate while not containing excess liquid, and 6 and 7 indicate diarrhoea. Some media describe type 4 as "ghost poop" or "perfect poop". In the initial study, in the population examined in this scale, the type 1 and 2 stools were more prevalent in females, while the type 5 and 6 stools were more prevalent in males; furthermore, 80% of subjects who reported rectal tenesmus (sensation of incomplete defecation) had type 7. These and other data have allowed the scale to be validated. The initial research did not include a pictorial chart with this being developed at a later point. The Bristol stool scale is also very sensitive to changes in intestinal transit time caused by medications, such as antidiarrhoeal loperamide, senna, or anthraquinone with laxative effect.
Prostaglandin H2 (PGH2), or prostaglandin H2 (PGH2), is a type of prostaglandin and a precursor for many other biologically significant molecules. It is synthesized from arachidonic acid in a reaction catalyzed by a cyclooxygenase enzyme. The conversion from arachidonic acid to prostaglandin H2 is a two-step process. First, COX-1 catalyzes the addition of two free oxygens to form the 1,2-dioxane bridge and a peroxide functional group to form prostaglandin G2 (PGG2). Second, COX-2 reduces the peroxide functional group to a secondary alcohol, forming prostaglandin H2. Other peroxidases like hydroquinone have been observed to reduce PGG2 to PGH2. PGH2 is unstable at room temperature, with a half life of 90–100 seconds, so it is often converted into a different prostaglandin. PGH2 is produced by every type of cell except for red blood cells and has a wide range of effects in the body.
== History == Michael Lesch was a medical student at Johns Hopkins and William Nyhan, a pediatrician and biochemical geneticist, was his mentor when the two identified LNS and its associated hyperuricemia in two affected brothers, ages 4 and 8. Lesch and Nyhan published their findings in 1964. Within three years, the metabolic cause was identified by J. Edwin Seegmiller and his colleagues at the NIH.
Sources: en.wikipedia.org
== Reactions == The chemistry of dichloroacetic acid is typical for halogenated organic acids. It is an alkylating agent. It forms esters. It is a member of the chloroacetic acids family. As such it is more acidic than acetic acid. It fully dissociates into dichloroacetate when dissolved in water, consistent with it pKa of 1.35, pure dichloroacetic acid is classed as a strong organic acid; it is very corrosive and extremely destructive to tissues of the mucous membranes and upper respiratory tract via inhalation.
== Enzyme activity == Activated by calcium, the enzyme digests proteins preferentially after hydrophobic amino acids (aliphatic, aromatic and other hydrophobic amino acids). Although calcium ions do not affect the enzyme activity, they do contribute to its stability. Proteins will be completely digested if the incubation time is long and the protease concentration high enough. Upon removal of the calcium ions, the stability of the enzyme is reduced, but the proteolytic activity remains. Proteinase K has two binding sites for Ca2+, which are located close to the active center, but are not directly involved in the catalytic mechanism. The residual activity is sufficient to digest proteins, which usually contaminate nucleic acid preparations. Therefore, the digestion with Proteinase K for the purification of nucleic acids is usually performed in the presence of EDTA (inhibition of metal-ion dependent enzymes such as nucleases). Proteinase K is also stable over a wide pH range (4–12), with a pH optimum of pH 8.0. An elevation of the reaction temperature from 37 °C to 50–60 °C may increase the activity several times, like the addition of 0.5–1% sodium dodecyl sulfate (SDS) or Guanidinium chloride (3 M), Guanidinium thiocyanate (1 M) and urea (4 M) . The above-mentioned conditions enhance proteinase K activity by making its substrate cleavage sites more accessible. Temperatures above 65 °C, trichloroacetic acid (TCA) or the serine protease-inhibitors AEBSF, PMSF or DFP inhibit the activity.
== Geography == Perhaps partly because the range runs through large portions of both the United States and Canada, and partly because the range was formed over numerous geologic time periods, one of which is sometimes termed the Appalachian orogeny, writing communities struggle to agree on an encyclopedic definition of the mountain range. However, each of the governments has an agency that informs the public about the major landforms that make up the countries, the United States Geological Survey (USGS) and the Geological Survey of Canada (GSC). The landforms are referred to as physiographic regions. The regions create precise boundaries from which maps can be drawn. The Appalachian Highlands is the name of one of the eight physiographic regions of the contiguous 48 United States. The Appalachian Uplands is the name of one of seven physiographic regions of Canada.
Solanine is a glycoalkaloid poison found in species of the nightshade family within the genus Solanum, such as the potato (Solanum tuberosum). It can occur naturally in any part of the plant, including the leaves, fruit, and tubers. Solanine has pesticidal properties, and it is one of the plant's natural defenses. Solanine was first isolated in 1820 from the berries of the European black nightshade (Solanum nigrum), after which it was named. It belongs to the chemical family of saponins.
From the evident difference in the transport of solution and channel appearance, one can identify the separation effect for the determination of blood type. Noiphung et al. at 2014 followed up an approach in paper-based microfluidic blood typing using antibodies to cause red blood cells agglutination, and the group designed a new paper-based analytical device (PAD) for blood grouping that can be used for the synchronous performation of Rh and forward and reverse ABO blood grouping on the same device. Forward grouping is a blood typing procedure whereby patient red blood cells are mixed with Anti-A and Anti-B reagents. On the other hand, reverse typing is a blood typing procedure where patient serum is mixed with reagent A cells and reagent B cells. The results should be the opposite of forward typing. The designed device has two sides: forward (F) side, made of chromatography paper with three channels spotted with 1.5 mL Anti-A, Anti-B, and Anti-D antibody solutions each, and reverse (R) side, made with blood separation membrane and connected to A-type and B-type antibodies channels. The PAD is fabricated using a combination of wax dipping technologies to join Whatman chromatography paper and blood separation membrane. The device included three wax-printed channels for forward grouping, two of which were also applied for reverse grouping. While R-side was capable for whole blood sample analysis, Noiphung's group found that whole blood samples are too viscous to be directly applied on a paper-side of the device.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.